KEY POINTS
- Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion.
- The deal centers on TERN-701, a promising oral treatment for chronic myeloid leukemia that could challenge existing market leaders.
- This strategic expansion aims to fortify Merck’s cancer portfolio as the company prepares for the upcoming patent expiration of its top-selling drug, Keytruda.
Global healthcare leader Merck is significantly expanding its reach in the hematology sector through a multibillion-dollar buyout of Terns Pharmaceuticals. The New Jersey-based pharmaceutical giant announced on Wednesday that it will pay $53 per share for the clinical-stage biotech firm. This price represents a notable premium over Terns’ recent average trading value and brings the total equity value of the deal to roughly $6.7 billion. The move is widely seen as a proactive measure to diversify Merck’s revenue streams ahead of 2028, when its flagship immunotherapy treatment, Keytruda, is scheduled to lose patent protection.
The centerpiece of the acquisition is TERN-701, an investigational oral therapy designed to treat chronic myeloid leukemia (CML), a rare form of blood and bone marrow cancer. Unlike many current treatments that target the active site of certain proteins, TERN-701 utilizes an allosteric mechanism, binding to a specific pocket to inhibit the signaling that drives cancer growth. Recent clinical data presented at major medical conferences indicated that the drug is highly effective, even in patients who had failed to respond to previous therapies. Merck executives believe the candidate has the potential to become a best-in-class option, offering a more convenient and better-tolerated alternative for long-term disease management.
By integrating Terns’ specialized research into its broader oncology division, Merck aims to accelerate the late-stage development of this leukemia asset. The company plans to initiate pivotal trials that could position TERN-701 as a direct competitor to established treatments currently dominated by other pharmaceutical majors. Industry analysts have noted that the drug’s unique profile may allow it to capture a significant portion of the multibillion-dollar CML market. Beyond its primary oncology applications, the acquisition provides Merck with additional scientific expertise in small-molecule drug discovery, which could yield further breakthroughs across its hematology pipeline.
This transaction follows a series of strategic investments by Merck aimed at building a “post-Keytruda” future. As the world’s top-selling cancer drug, Keytruda currently accounts for a substantial percentage of the company’s annual sales, making the development of new high-impact medicines a top corporate priority. Merck’s leadership has emphasized that while their current portfolio is strong, they are aggressively seeking out differentiated assets that can sustain growth into the next decade. The Terns buyout aligns with this philosophy, targeting a niche but high-value therapeutic area where there remains a significant unmet medical need for patients with resistant forms of leukemia.
The financial structure of the deal involves a tender offer for all outstanding shares of Terns Pharmaceuticals. Both companies’ boards of directors have already approved the merger, and the transaction is expected to close during the second quarter of 2026. Following the completion of the deal, Terns will become a wholly-owned subsidiary of Merck. While the acquisition will result in a near-term charge to Merck’s earnings, the company expects the long-term commercial potential of TERN-701 to drive substantial shareholder value. The integration will also see Terns’ research and development team collaborate closely with Merck Research Laboratories to streamline the regulatory approval process.
Market reaction to the announcement has been largely positive, reflecting confidence in Merck’s ability to identify and integrate high-potential biotech assets. For Terns, the deal provides the massive resources and global infrastructure required to bring a specialized cancer treatment to the mass market. For the broader pharmaceutical industry, the $6.7 billion agreement serves as a clear indicator that large-scale mergers and acquisitions remain a primary tool for Big Pharma companies looking to refresh their pipelines. As Merck continues to pivot toward its next generation of treatments, the success of TERN-701 will be a key metric in evaluating the company’s long-term oncology strategy.
